
FDA Finalizes Guidances to Accelerate Development of Next-Generation Sequencing Tests
The FDA has finalized 2 guidances to accelerate the development of next-generation sequencing (NGS)–based tests, the agency announced on Thursday. The guidances provide recommendations for designing, developing, and validating tests that use NGS.
The FDA has finalized 2 guidances to accelerate the development of reliable, beneficial next-generation sequencing (NGS)—based tests,
Playing a large role in the advancement of precision medicine, NGS works by examining a person’s DNA to pinpoint genetic variations that may determine whether a person has, or is at risk for developing, a genetic disease and can help inform treatment decisions. Rather than detecting chemical changes associated with a condition, NGS scans millions of DNA changes in a single test to determine the cause of a person’s disease or condition.
The first guidance, “
The guidance also provides product developers direction on how to use these databases to support the clinical validation of the NGS tests they are developing, which will provide them with an efficient path for marketing clearance for approval of a new test, according to the release.
The second guidance, “
“As disease detection technologies rapidly evolve, so too must the FDA’s approach to reviewing these new innovations,” said FDA Commissioner Scott Gottlieb, MD, in a statement. “The new policies issued today provide a modern and flexible framework to generate data needed to support the FDA’s review of NGS-based tests and give developers new tools to support the efficient development and validation of these technologies.”
Gottlieb also announced the release of these guidances during his
Last month,
The NCD followed the FDA’s approval of the
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.